| This week's sponsor is TD2. | | | The A-Z Guide of DMPK Assays, and How to Find the Right One
You might know you need to conduct drug metabolism and pharmacokinetic (DMPK) analysis, but which tests are right for your project? And are you doing them at the right time? With a complete guide to assays, this free white paper will help you learn how, when and where to find the right assay mix for your preclinical work. |
Today's Rundown GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round Menlo Therapeutics' serlopitant comes up short in chronic cough Phase 3 rare disease flop leaves Diurnal reeling Akcea sets off after Alnylam’s hATTR therapy in U.S., but with a handicap Xencor’s lead lupus antibody misses phase 2 endpoint Lilly makes waves with next-gen diabetes drug, but GLP-1 rivals needn't panic: analysts Featured Story | | | Monday, October 8, 2018 GlaxoSmithKline has helped Sitryx to a $30 million (€26 million) funding round. Newly formed British biotech Sitryx will use the money and its relationship with GSK to move immunometabolism assets toward human testing. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Monday, October 8, 2018 Just six months after its lead drug flunked a phase 2 trial in atopic dermatitis, Menlo is reporting another fail—this time in chronic cough. Monday, October 8, 2018 Diurnal’s Chronocort has failed to beat the control in a phase 3 congenital adrenal hyperplasia trial. The modified-release preparation of hydrocortisone was no better at controlling sex hormones than conventional glucocorticoid doses, sending Diurnal’s stock into a downward spiral. Monday, October 8, 2018 Ionis spinout Akcea has its first FDA approval in the bag, getting a green light for rare disease hATTR drug Tegsedi, but it will be burdened with a black box warning as it chases rival Alnylam. Friday, October 5, 2018 Topline results from a phase 2 study showed Xencor’s lead CD19-targeting antibody missed its primary endpoint in lupus, but the company described the data as a “positive trend” that still contained a “promising treatment effect” worthy of future study. Monday, October 8, 2018 Last week, Eli Lilly unveiled positive data for a new diabetes drug with serious potential to disrupt the GLP-1 market. But its rivals don't need to hunker down, analysts said. | This week's sponsor is PharmaCord. | | | |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: SAP Collaborate in a digital world to improve patient outcomes. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn more about two main areas where a drug developer can face significant obstacles during biologics development. Sponsored by: RWS Life Sciences Examine the linguistic and cultural considerations of global eCOA and BYOD. Sponsored by: Amazon Web Services Download our new eBook to learn how Healthcare and Life Sciences organizations are taking advantage of solutions from AWS and the AWS Partner Network to obtain value from critical data. Sponsored by: Covance FSPx Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries. Sponsored by: Covance FSPx Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Veeva A top 20 pharma and growing biotech re-engineer regulatory processes. Sponsored by: Sciformix Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be! Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 – Registration closes 30 October - Register Now! November 14-15, 2018 | Boston, MA | Registration closes on the 30 of October 2018 due to the need for participants to complete pre-Boot Camp preparations. Register now and start preparing for this intensive training in drug development. AI World Conference and Expo 2018 Monday, December 3, 2018 | 10/5/18 – Early Deadline PepTalk: The Protein Science Week January 14, 2019 | October 19, 2018 – Early Deadline
Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Fierce Innovation Awards: Life Sciences Edition 2018 Welcome to the inaugural Neuromuscular Drug Development Summit October 29-31, 2018 | Boston, MA, USA FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Immersion November 1-2, 2018 | Boston, MA European Healthcare Compliance Certification Program November 5-8, 2018 | Paris, France Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Immersion December 5-6, 2018 | San Diego, CA BioBasics: Biotech For The Non-Scientist December 5-6, 2018 | Boston, MA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA T Cell Based Immunotherapy: A Deeper Dive III Conference February 28 - March 3, 2019 | 